INOVIQ signs validation deal with Sonic Healthcare USA
Key points
- INOVIQ partnered with Sonic Healthcare USA to validate its EXO-OC ovarian cancer test.
- The deal grants an option to license the test as a laboratory-developed test across the US.
- Updated algorithm data show 92.3% early-stage sensitivity and 98% specificity.
INOVIQ (ASX:IIQ) has signed a validation and licence option agreement with Sonic Healthcare USA to optimise and validate its EXO-OC ovarian cancer early-detection test.
Under the terms of the deal, the company will transfer its test to a laboratory in Rye Brook, New York, to conduct validation testing.
The agreement grants Sonic Healthcare USA an option to license the test as a laboratory-developed test following validation.
Dr Mohamed Salama, Chief Medical Officer of Sonic Healthcare USA, said: “EXO-OC has the potential to address a significant unmet need in ovarian cancer detection, where earlier diagnosis may improve outcomes for women.”
Updated clinical data demonstrate that the EXO-OC algorithm achieved 92.3% sensitivity for stage 1/2 detection and 92.5% sensitivity across all stages, alongside 98% specificity.
Following the announcement, the INOVIQ share price was unchanged at $0.16.
The commercialisation pathway targets Sonic Healthcare USA's network, which serves approximately 20 million physicians and patients across the US market.
INOVIQ remains focused on commercialising its proprietary exosome-based diagnostics portfolio to expand cancer detection capabilities globally.
Frequently asked questions
More from Australia
Energy North drops timeline for remote data centre
Ingenia Communities Group matches Warburg Pincus takeover proposal
KMD Brands grants exclusivity to Bluestar Alliance
Pioneer Credit secures major bank deal for $14.4M
Westpac reports flat full-year net profit of $7B
Australian federal departments overspent by $2B
